{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.7","upperLimit":"8.9","value":"8.1"},{"groupId":"OG001","lowerLimit":"3.8","upperLimit":"7.9","value":"5.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"title":"DOR by BICR Assessment"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"8.9","value":"7.0"},{"groupId":"OG001","lowerLimit":"4.2","upperLimit":"6.1","value":"4.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"DOR by LIR Assessment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"DOR was defined as the time from the date a response of CR or PR was first documented until the date of the first documentation of disease progression or date of death (whichever occurred first). DOR was analyzed based on both BICR and LIR assessments. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Disease progression was defined as an increase of greater than 20% in the sum of the LD of target lesions and a 5 mm absolute increase, taking as a reference the smallest sum LD recorded since the baseline assessment or the appearance of new non-target lesions. DOR was estimated using Kaplan-Meier estimate.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received sacituzumab govitecan 10 mg/kg of body weight, administered as a slow IV infusion on Days 1 and 8 of a 21-day treatment cycle until progression of disease, occurrence of unacceptable AEs, or another treatment discontinuation criterion was met (up to 40.1 months).","id":"OG000","title":"Sacituzumab Govitecan"},{"description":"Participants received TPC (ie, eribulin, capecitabine, gemcitabine, or vinorelbine), administered as a single-agent treatment that was determined by the investigator before participant randomization until progression of disease, occurrence of unacceptable AEs, or another treatment discontinuation criterion was met. Dosing per NCCN guidelines (with dose modifications for if toxic)\n\n* Eribulin was administered IV at a dose 1.4 mg/m\\^2 at North American sites and 1.2 mg/m\\^2 at European sites on Days 1 and 8 of a 21-day cycle (up to 22.5 months).\n* Capecitabine 1000 to 1250 mg/m\\^2 was administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest period (up to 12.9 months).\n* Gemcitabine 800 to 1200 mg/m\\^2 was administered IV on Days 1, 8, and 15 of a 28-day cycle (up to 22.3 months).\n* Vinorelbine 25 mg/m\\^2 was administered as a weekly IV injection (up to 8.1 months). Vinorelbine was not allowed as TPC for any participant with Grade 2 neuropathy.","id":"OG001","title":"Treatment of Physician's Choice (TPC)"}],"paramType":"MEDIAN","populationDescription":"Participants in the ITT Population with confirmed objective response were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 42.8 months","title":"Duration of Response (DOR) by BICR and LIR Assessment","type":"SECONDARY","unitOfMeasure":"months"}